SOURCES SOUGHT
65 -- TR-FRET Nuclear Receptor Biochemical Assay Kits - FXR Publication
- Notice Date
- 7/20/2015
- Notice Type
- Sources Sought
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211 - MSC 9559, Bethesda, Maryland, 20892, United States
- ZIP Code
- 20892
- Solicitation Number
- HHS-NIH-NIDA-SSSA-SBSS-15-627
- Archive Date
- 8/11/2015
- Point of Contact
- Matthew P. Antonini, Phone: 301-402-1678
- E-Mail Address
-
matthew.antonini@nih.gov
(matthew.antonini@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This is a publication that gives additional background about the research of Tox21. INTRODUCTION: This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This notice is posted concurrently with HHS-NIH-NIDA-SSSA-SS-15-628, which is for businesses of all sizes. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. BACKGROUND: The National Institutes of Health (NIH) is the nation's leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people's health and save lives. The National Center for Advancing Translational Sciences (NCATS) Toxicology in the 21st Century (Tox21) Program currently screens approximately 10,000 environmental chemicals and drugs for their potential of posing adverse effects on humans and environment. One focus area of the Tox21 program is to develop a battery of high-throughput screening assays for characterization of the mode of action of these potential hazardous chemicals. As part of the U.S. Tox21 program we require nuclear receptor biochemical assay kits as described below. PURPOSE AND OBJECTIVES: A time-resolved fluorescence resonance energy transfer (TR-FRET FXR) assay kit was previously used to study mode of action of FXR-active Tox21 chemicals in the attached publication entitled "Quantitative Profiling of Environmental Chemicals and Drugs that Modulate Farnesoid X Receptor." We further extended and evaluated the TR-FRET assay format for other Tox21-relevant nuclear receptors the androgen receptor (AR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), liver X receptor alpha (LXR alpha), and farnesoid X receptor (FXR). These receptors are primary targets accounting for endocrine disruption and many metabolic diseases such as diabetes and cholestasis. Upon activation, these receptors bind to the corresponding agonist compounds and coactivator proteins and cause differential outcomes to downstream effectors. We previously used beta-lactamase and luciferase reporter gene technology on AR, CAR, and FXR to identify potentially hazardous environmental chemicals and drugs that exert toxicity effects via these receptors. However, the data only provide whether a certain chemical induce or inhibit expression of the reporter genes in cellular environment. Therefore, additional assays that measure receptor binding and/or coactivator recruitment are needed to further study mechanisms of actions of the identified AR-, CAR-, and FXR-active chemicals. To proper translate metabolic outcomes of CAR- or FXR-active chemicals, it is also important to test chemical toxicity against other functionally relevant receptors such as PXR and LXR alpha. To enable mode of action studies of over 1000 FXR-active, CAR-active, and AR-active Tox21 chemicals in the same biochemical TR-FRET assay formats, Tox21 is purchasing ten kits of each aforementioned TR-FRET biochemical nuclear receptor assay. The assays will enable understanding of compound mechanisms for relevant toxicology and pharmacology at biochemical level. PROJECT REQUIREMENTS: The contractor shall provide ten (10) each biochemical nuclear receptor assay kits in TR-FRET coactivator or TR-FRET competitive assay formats for the following receptors: •constitutive androstane receptor (CAR) •liver X receptor alpha (LXR alpha) •pregnane X receptor (PXR) •farnesoid X receptor (FXR) •androgen receptor (AR) The assay kits must enable quantification of receptor binding and/or coactivator recruitment by time-resolved fluorescence resonance energy transfer (TR-FRET) between a donor-labeled antibody binding to the receptor protein of interest and an acceptor-labeled coactivator protein associating with the activated receptor. Due to the nature of the research, these assay products must (1) be biochemical nuclear receptor assays and (2) use TR-FRET coactivator or competitive assay format. ANTICIPATED PERIOD OF PERFORMANCE: Require delivery date within 6 weeks after receipt of order. PLACE OF PERFORMANCE All kits must be delivered to the following location for inspection and acceptance: 9800 Medical Center Drive Rockville, Maryland 20850 CAPABILITY STATEMENT / INFORMATION SOUGHT: Respondents must provide clear and convincing documentation of their capability of providing the services specified in this notice. Also, information must be provided in sufficient details of the respondents' (a) staff expertise, including their availability, experience, and formal and other training; (b) current in-house capability and capacity to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and management capability; and (e) examples of prior completed Government contracts, references, and other related information. Respondents must provide their DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HUBZone) pursuant to the applicable NAICS code AND any other information that may be helpful in developing or finalizing the acquisition requirements. Finally, respondents are also encouraged to provide a general overview of the respondent's opinions about the difficulty and/or feasibility of the potential requirement, and any information regarding innovative ideas or concepts that may be applicable. SUBMISSION INSTRUCTIONS: One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2" x 11" paper size, with 1" top, bottom, left and right margins, and with single or double spacing. The information submitted must be must be in an outline format that addresses each element of the "PROJECT REQUIREMENTS" and each element of the "CAPABILITY STATEMENT / INFORMATION SOUGHT" paragraphs above. A cover page and an executive summary may be included but is not required. The response is limited to ten (10) pages. The 10-page limit does not include the cover page, executive summary, or references, if requested. The response must include the respondents' technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. All responses to this notice must be submitted electronically to the Contract Specialist (Facsimile responses are NOT accepted.): Matthew Antonini Contract Specialist NIH/NIDA/SSSA matthew.antonini@nih.gov DISCLAIMER AND IMPORTANT NOTES: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. CONFIDENTIALITY: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/HHS-NIH-NIDA-SSSA-SBSS-15-627/listing.html)
- Place of Performance
- Address: 9800 Medical Center Drive, Rockville, Maryland, 20850, United States
- Zip Code: 20850
- Zip Code: 20850
- Record
- SN03803591-W 20150722/150720235616-1dc06b57035b975e80e02d2ff3672fbc (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |